Press Room

Event

RDD Europe 2015

Start
Tuesday, May 05, 2015 - 00:00
End
Friday, May 08, 2015 - 00:00
Location: Nice, France
Booth Number: Table nr. 32

RDD Europe 2015 will be held from Tuesday 5th May until Friday 8th May 2015 at the Palais des Congres d'Antibes, Nice, France. Hovione will be present with a table (nr. 32), a presentation, a workshop and a set of posters.

Contact us if you would like to schedule a meeting or to find more about the Hovione posters at RDD.

contact us button | Hovione
http://go.hovione.com/l/47122/2015-04-27/67pjt

 

HOVIONE'S PRESENTATION
Optimized Composite Particles for API-independent Formulations with Enhanced Performance
Speaker: Eunice Costa, PhD (Scientist, Drug Product Development)
Date: Friday, May 5, 2015
Time: 8:30 AM

HOVIONE'S WORKSHOP
Trends in Inhalation Drug Development: Particle Engineering and Formulation Strategies
Speakers: Eunice Costa, PhD (Scientist, Drug Product Development)
                  Filipe Neves, PhD (Senior Scientist, Group Leader, Drug Product Development)
Date: Wednesday, May 6, 2015 
Time: tbd - afternoon from 2:00 to 6:00 PM

  • Introduction: This workshop addresses trends in particle engineering (PE) technologies, and formulation strategies to overcome problems during the development of inhalation drugs. Participants will gain insight into innovative approaches via comprehensive and diverse case studies chosen to illustrate the complexity of manufacturing processes. 
     
  • Workshop Content: Participants will learn the fundamentals of inhalation delivery, together with an overview of market trends and basic concepts associated with metered dose inhalation (MDI) and dry powder inhalation (DPI); for the latter platform, carrier based and composite particles based approaches will be emphasized. The impact of different particle engineering technologies on the final performance of both MDI and DPI (carrier based) products will be discussed. Case studies will link API properties (measured by cutting edge techniques) and formulation strategy, with the overall success of a given delivery platform. Lastly, DPI formulation based on spray dried composite particle approaches will be explored using case studies covering formulation development and process scale-up.
     
  • Outcome for Participants: The participants will gain insight into several innovative approaches, including a number of comprehensive and diverse case studies, which will illustrate the complex relationships linking inhaler design to particle engineering and formulation strategies.
     

POSTERS

Impact of the Size-Reduction Technology on the Performance of Suspension Pressurized Metered Dosed Inhalers: Benchmarking with Dry Powder Inhalers
Eunice Costa

Performance Optimization in Early DPI Development: Enabling High Dosage Drug Delivery to the Lungs Through Orifice-Based Aerosolization
João Fernandes

Benchmarking Gravimetric FSI vs ACI: Can We Expedite Aerodynamic Performance Evaluation for Composite Powders?
Isabel Lopes

Aerodynamic Performance of DPIs: Predicting the Impact of Carrier-Based Formulation Parameters
Filipa Maia

API Influence & Stability Assessment of Spray Dried Composite Particles
Cláudia Moura

Optimizing Trade-Offs Between Product Performance and Process Efficiency via Powder Rheology
Maria Palha

 

 

Also in the Press Room

See All

Hovione is a global contract development and manufacturing organization (CDMO) company founded in Portugal in 1959. With approximately 2,400 team members worldwide, the company provides comprehensive services for drug substances, drug intermediates, and drug products in countries around the world. Japan in particular plays a very important role in Hovione's global strategy, and in 2017 it established a Japanese subsidiary in Osaka. The company plans to actively invest in further strengthening its organization and recruiting personnel. With development labs strategically located in Lisbon, Portugal, and New Jersey, USA, Hovione consistently provides superior solutions tailored to complex pharmaceutical challenges. Hovione is recognized globally for its scientific excellence, technological innovation, and customer-centric and integrated approach. Leveraging cutting-edge capabilities in chemical synthesis, particle engineering, and formulation development, the company supports its partners throughout the entire pharmaceutical life cycle.   Read the full article in Japanese Read the article translated in English   Visit the Yakuji Nippo online      

Press Clipping
Yakuji Nippo Magazine, 2 July 2025

Solving Complex Pharmaceutical Challenges

Jul 10, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping
Pharmiweb.com, 25 June 2025

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025

CDMO Hovione and biotechnology company Firstgene Life Sciences (of Xlife Sciences) have collaborated to advance Hovione’s drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC). “We are proud to advance the development of innovative oncology treatments that address a critical unmet need for precision gene expression at the tissue level,” said Hovione CEO Dr Jean-Luc Herbeaux. The virus-like particle technology will be engineered and functionalised for the specific carcinoma cell type using therapeutically validated AAVs, including a novel primer compound. Hovione will be responsible for molecular engineering, the supply of tailor-made virus-like particles and the execution of proof-of-concept studies. “HCC, the most common liver cancer and a leading cause of cancer-related death, continues to represent a major unmet medical need,” said Firstgene managing director Dr Alexander Zink. “The combination of Hovione’s expertise in complex chemistry and particle engineering and the commercialisation expertise of Xlife Sciences positions Firstgene well to offer patients potential new safe and effective therapy options.”   Read the full article at scientistlive.com    

Press Clipping
Scientist Live, 12 May 2025

Partnership advances liver cancer treatment

May 12, 2025

Also in Events

See All